1. International Conference on Harmonisation (ICH) Q3A(R2), Impurities in new drug substances. https://www.ich.org/page/quality-guidelines, 2006 (accessed 25 October 2006).
2. International Conference on Harmonisation (ICH) Q3B(R2), Impurities in new drug products. https://www.ich.org/page/quality-guidelines, 2006 (accessed 2 June 2006).
3. International Conference on Harmonisation (ICH) M7(R2), Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. https://www.ich.org/page/multidisciplinary-guidelines, 2017 (accessed 31 March 2017).
4. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers;Jung;Clin. Ther.,2010
5. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction;Limin;Expert. Opin. Drugs,2010